Circassia Group (CIR)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

29.80p
   
  • Change Today:
    -0.68p
  • 52 Week High: 32.00
  • 52 Week Low: 12.93
  • Currency: UK Pounds
  • Shares Issued: 397.40m
  • Volume: 46,357
  • Market Cap: £118.42m
  • RiskGrade: 7

Circassia to report Phase 3 trial results for cat allergy treatment in coming weeks

By Alexander Bueso

Date: Wednesday 25 May 2016

LONDON (ShareCast) - (ShareCast News) - Circassia Pharmaceuticals kicked off phase-three trials for its grass allergy treatment, the second imunotherapy programme for which it was seeking regulatory approval, and said it was on-track to report the results of its phase-three clinical trials for its Cat allergy treatment using its SPIRE technology platform.
The latest phase-three test was broken into two parts, with results form Part A due in the second half of 2017 and those from Part B, which would be conducted on a larger population size, due in the backhalf of 2018.

Analysts at Numis viewed that staging of the Grass-SPIRE test as a means to also factor in the results of the Phase three Cat-SPIRE trial into Grass-SPIRE.

"In the event of a failure, Circassia has a fast-growing specialty asthma diagnostics platform broad pipeline of respiratory generics and a solid balance sheet, and we continue to see an attractive risk reward profile with a 610p target price if successful and 177p if unsuccessful with further upside from the diagnostics (primary care) and generics (generic Advair and novel triple) portfolio on a 12-month view," Numis analysts Paul Cuddon, Sally Taylor and Stefan Hamill said in a research note sent to clients.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

CIR Market Data

Currency UK Pounds
Share Price 29.80p
Change Today -0.68p
% Change -2.21 %
52 Week High 32.00
52 Week Low 12.93
Volume 46,357
Shares Issued 397.40m
Market Cap £118.42m
RiskGrade 7

CIR Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
4.58% below the market average4.58% below the market average4.58% below the market average4.58% below the market average4.58% below the market average
85.19% above the sector average85.19% above the sector average85.19% above the sector average85.19% above the sector average85.19% above the sector average
Price Trend
20.59% above the market average20.59% above the market average20.59% above the market average20.59% above the market average20.59% above the market average
13.79% below the sector average13.79% below the sector average13.79% below the sector average13.79% below the sector average13.79% below the sector average
Income Not Available
Growth
42.93% above the market average42.93% above the market average42.93% above the market average42.93% above the market average42.93% above the market average
18.92% above the sector average18.92% above the sector average18.92% above the sector average18.92% above the sector average18.92% above the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 0
Sell 0
Strong Sell 1
Total 1
strong_sell
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CIR Dividends

No dividends found

Trades for 25-Nov-2020

Time Volume / Share Price
09:50 3,244 @ 29.80p
09:50 6,380 @ 29.80p
09:40 2,500 @ 29.85p
09:39 250 @ 30.65p
09:39 19,113 @ 29.60p

Top of Page